Читать книгу Autoimmune Liver Disease - Группа авторов - Страница 89

Studies of two strategies to produce iTregs specific for autoantigens are in progress (Table 2.3) [1]. The first strategy is to increase the proliferation of existing iTreg populations by infusion of low doses of IL‐2, which is being studied in hematopoietic stem cell transplantation, graft‐versus‐host disease, T1DM, HCV‐associated vasculitis, and SLE. The second strategy involves generating antigen‐specific iTregs from peripheral blood mononuclear cells ex vivo for infusion. iTregs specific for CYP2D6 autoantigens in type 2 AIH have been produced, but not yet infused.